Company intelligence / Profile preview
Foshan Rexiu Biotechnology
Foshan, Guangdong Sheng, Chinaheatshock.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Foshan Rexiu Biotechnology is a Chinese biotech company focused on early-stage drug discovery, particularly fusion proteins and recombinant polypeptides targeting HSP90B1 for rare diseases, immune system disorders, and metabolic conditions. As of January 2025, all known programs remain at the discovery stage with no clinical results reported[7][6].
- Therapeutic areas
- Metabolic DisordersRare DiseasesImmunology
- Modalities
- Fusion proteinRecombinant polypeptide
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Foshan Rexiu Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Foshan Rexiu Biotechnology.